XML 54 R20.htm IDEA: XBRL DOCUMENT v3.19.3
Share Capital (Tables)
 9 Months Ended
Sep. 30, 2019
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]  
Schedule of Stock Option Plans
A summary of the status of the Company’s option plans as of September 30, 2019 and changes during the period then ended is presented below: 
Nine months ended September 30, 2019
Unaudited
Number
of options		Weighted
average
exercise
price
Outstanding at beginning of year14,438,215  $13.56  
Granted1,496,161  49.43  
Exercised(4,914,918) 10.55  
Forfeited and canceled(144,403) 19.91  
Outstanding as of September 30, 201910,875,055  $19.77  
Exercisable options3,444,478  $14.61  
Schedule of RSU's
A summary of the status of the Company’s RSUs as of September 30, 2019 and changes during the period then ended is presented below: 
Nine months ended September 30, 2019
Unaudited
Number
of RSUs		Weighted
average
grant date fair value
price
Unvested at beginning of year1,613,197  14.04  
Granted597,583  50.71  
Vested(736,411) 13.36  
Forfeited and cancelled(24,356) 34.32  
Unvested as of September 30, 20191,450,013  29.16  
Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model
The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. We assessed fair value using the following underlying assumptions: 
Nine months ended September 30,Year ended December 31,
2018
20192018
UnauditedAudited
Stock Option Plans
Expected term (years)
5.50-6.50
5.50-6.25
5.50-6.25
Expected volatility
55%-61%
52%-55%
52%-55%
Risk-free interest rate
1.90%-2.40%
2.70%-2.89%
2.70%-2.99%
Dividend yield0.00 %0.00 %0.00 %
ESPP
Expected term (years)0.500.500.50
Expected volatility
44%-62%
45%-53%
45%-53%
Risk-free interest rate
2.10%-2.51%
1.61%-2.14%
1.61%-2.14%
Dividend yield0.00 %0.00 %0.00 %
Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards
The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2019 and 2018 and the year ended December 31, 2018 was:
Three months ended September 30,Nine months ended September 30,Year ended December 31,
2018
2019201820192018
UnauditedUnauditedAudited
Cost of revenues$605  $464  $1,626  $891  $1,261  
Research, development and clinical trials2,202  1,223  5,203  3,415  4,709  
Sales and marketing3,368  1,979  8,585  5,309  7,393  
General and administrative8,163  6,813  22,305  19,590  26,483  
Total share-based compensation expense$14,338  $10,479  $37,719  $29,205  $39,846